伏立康唑致肺移植受者皮肤鳞状细胞癌危险因素及机制研究进展  

Risk factors and mechanisms for skin squamous cell carcinoma in lung transplant recipients induced by voriconazole

作　　者：吕鹏 张京莉[1] 王运红 马芬芬 张玉[3] 黄怡菲 LYU Peng;ZHANG Jingli;WANG Yunhong;MA Fenfen;ZHANG Yu;HUANG Yifei(Department of Pharmacy,Taihe Country People’s Hospital,Taihe Anhui 236600,China;Department of Clinical Pharmacy,Fudan University Affiliated Pudong Medical Center,Shanghai 201399,China;Department of Pharmacy,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan Hubei 430022,China)

机构地区：[1]安徽省太和县人民医院药剂科,安徽太和236600 [2]复旦大学附属浦东医院临床药学室,上海201399 [3]华中科技大学同济医学院附属协和医院药学部,湖北武汉430022

出　　处：《中国药物警戒》2023年第5期595-600,共6页Chinese Journal of Pharmacovigilance

基　　金：国家重点研发计划资助项目(2017YFC0909900);阜阳市卫生健康委科研立项课题青年项目(FY2021-106)。

摘　　要：伏立康唑作为广谱抗真菌药物,常作为肺移植术后预防和治疗侵袭性曲霉菌病的首选药物,其耐受性良好、安全有效。随着临床的广泛应用,伏立康唑相关的皮肤鳞状细胞癌的个案报道和研究逐渐增多,常呈侵袭性和多灶性,已成为肺移植受者发生鳞状细胞癌的独立危险因素。本文综述了伏立康唑致肺移植受者出现皮肤鳞状细胞癌的危险因素和潜在机制,为临床合理应用提供一定的参考。Voriconazole is an effective broad-spectrum antifungal agent characterized by high tolerance,safety and effectiveness that is often used as the first choice for the prevention and treatment of invasive aspergillosis after lung transplantation.With wider clinical application,case reports of voriconazole-related cutaneous squamous cell carcinoma,which is often aggressive and multifocal in nature,are ticking up,making this drug an independent risk factor for squamous cell carcinoma in lung transplant recipients.This article reviews the risk factors and potential mechanisms for the development of squamous cell carcinoma induced by voriconazole in order to provide reference for rational clinical application.

关 键 词：伏立康唑 肺移植 皮肤鳞状细胞癌 危险因素 机制 

分 类 号：R978[医药卫生—药品] R994.11[医药卫生—药学]